Literature DB >> 12791472

Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.

Ken B Waites1, Donna M Crabb, Lynn B Duffy.   

Abstract

The MIC of gemifloxacin was compared with that of sparfloxacin, levofloxacin, moxifloxacin, gatifloxacin, ciprofloxacin, doxycycline, erythromycin, azithromycin and clarithromycin using 97 clinical isolates of Mycoplasma pneumoniae. MBCs of fluoroquinolones were determined for a subgroup of 12 isolates. Macrolides were the most potent agents with MIC(90)s for all drugs <or=0.001 mg/l. The doxycycline MIC(90) was 0.5 mg/l. Gemifloxacin MICs ranged from <or=0.001 to 0.25 mg/l. The gemifloxacin MIC(90) (0.125 mg/l) was equivalent to moxifloxacin and gatifloxacin, was 2-fold lower than sparfloxacin, 8-fold lower than levofloxacin and 32-fold lower than ciprofloxacin. MBCs for gemifloxacin were predominantly within 2-4 times the corresponding MIC values, indicating a bactericidal effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791472     DOI: 10.1016/s0924-8579(03)00060-8

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Antibiotic administration in the drinking water of mice.

Authors:  James O Marx; Daljit Vudathala; Lisa Murphy; Shelley Rankin; F Claire Hankenson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

2.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Community-acquired pneumonia related to intracellular pathogens.

Authors:  Catia Cillóniz; Antoni Torres; Michael Niederman; Menno van der Eerden; James Chalmers; Tobias Welte; Francesco Blasi
Journal:  Intensive Care Med       Date:  2016-06-08       Impact factor: 17.440

Review 4.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.